Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Comment by blogon May 13, 2009 10:23am
301 Views
Post# 15989430

RE: RE: RE: RE: RE: RE: details of deal

RE: RE: RE: RE: RE: RE: details of dealbromley,

My math is a little different than yours with respect to Paladin getting the 12% of revenue from Isotechnikas future deals. If Isotech can only get say 24% from a future collaboration in their regions then their share of revenue would be 12%, than assume this 12% equates to $1 in revenue, with a P.E ratio of 15 that would justify a share price of $15. The share price could have been $30 if they had the full 24%; a big difference. I realize there’s other aspects of this deal, but consider this part alone.

Bullboard Posts